HTLV-II down-regulates HIV-1 replication in IL-2-stimulated primary PBMC of coinfected individuals through expression of MIP-1α

Blood

Volumn 95, Issue 9, 2000, Pages 2760-2769

  Casoli, Claudio ^a   Vicenzi, Elisa ^b   Cimarelli, Andrea ^b   Magnani, Giacomo ^b   Ciancianaini, Paolo ^b   Cattaneo, Ercole ^b   Dall'Aglio, PierPaolo ^b   Poli, Guido ^b   Bertazzoni, Umberto ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNOMODULATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0034192221     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.9.2760.009k04_2760_2769     Document Type: Article

References (64)

1. Poiesz BJ, Sherman MP, Saksena NK, et al. The biology and epidemiology of the human T-cell lymphoma/leukemia viruses. In: Neu HC, Levy JA, Weiss RA, eds. Focus on HIV. Frontiers of Infectious Diseases. London, UK: Churchill-Livingston; 1993:189.
2. Gallo RC. The first human retrovirus. Sci Am. 1986;255:78.
3. Gessain A, Vernant JC, Maurs L, et al. Antibodies to human T-lymphotropic virus type-1 in patients with tropical spastic paraparesis. Lancet. 1985;2: 407.
4. Hall WW, Kubo T, Ijichi S, Takahashi H, Zhu SW. Human T cell leukemia/lymphoma virus, type II (HTLV-II): emergence of an important newly recognized pathogen. Semin Virol. 1994;5:165.
5. The HTLV European Research Network. Seroepidemiology of the human T-cell leukemia/lymphoma viruses in Europe. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:68.
6. Zella D, Mori L, Sala M, et al. HTLV-II infection in Italian drug abusers. Lancet. 1990;336:575.
7. Bartholomew C, Blattner W, Cleghorn F. Progression to AIDS in homosexual men co-infected with HIV and HTLV-I in Trinidad. Lancet. 1987;2:1469.
8. Lefrere JJ, Courouse AM, Mariotti M, et al. Rapid progression to AIDS in dual HIV/HTLV-I infection. Lancet. 1990;336:509.
9. Zack JA, Cann AJ, Lugo JD, Chen ISY. HIV-1 production from peripheral blood cells after HTLV-I induced mitogenic stimulation. Science. 1988; 240:1026.
10. Casoli C, Cimarelli A, Bertazzoni U. Cellular tropism of human T-cell leukemia virus type II enlarged to B lymphocytes in patients with high proviral load. Virology. 1995;206:1126.
11. Visconti A, Visconti L, Bellocco R, et al. HTLV-II/ HIV-1 coinfection and risk for progression to AIDS among intravenous drug users. J Acquir Immune Defic Syndr. 1993;6:1228.
12. Hershow RC, Galai N, Fukuda K, et al. An international collaborative study of the effects of Co-infection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. J Infect Dis. 1996;174:309.
13. Cimarelli A, Duclos CA, Gessain A, et al. Quantification of HTLV-II proviral copies by competitive polymerase chain reaction in peripheral blood mononuclear cells of Italian injecting drug users, central Africans, and Amerindians. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:198.
14. Magnani G, Elia GF, Casoli C, et al. Human T-cell leukemia virus type II infection among high risk group and its influence on HIV-1 disease progression. Eur J Epidemiol. 1995;11:527.
15. Green PL, Chen ISY. Regulation of human T cell leukemia virus expression. FASEB J. 1990;4:169.
16. Smith MR, Green WC. Molecular biology of the type I human T-cell leukemia virus (HTLV-I) and adult T-cell leukemia. J Clin Invest. 1991;87:761.
17. Siekevitz M, Josephs SF, Dukovich M, Peffer N, Wong-Staal F, Greene WC. Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I. Science. 1987;238:1575.
18. Parker SF, Parkins ND, Gitlin SD, Nabel GJ. A cooperative interaction of human T-cell leukemia virus type 1 Tax with the p21 cyclin-dependent kinase inhibitor activates the human immunodeficiency virus type 1 enhancer. J Virol. 1996;70: 5731.
19. Berger EA, Doms RW, Fenyo EM, et al. A new classification of HIV-1. Nature. 1998;391:240.
20. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 1997;185:621.
21. Scarlatti G, Tresoldi E, Bjorndal A, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med. 1997;3:1259.
22. + T cells. Science. 1995;270:1811.
23. Bertini R, Luini W, Sozzani S, et al. Identification of MIP-1 alpha/LD78 as a monocyte chemoattractant released by the HTLV-I-transformed cell line MT4. AIDS Res Hum Retroviruses. 1995;11: 155.
24. + CTL clones from patients with HTLV-I-associatad neurologic disease secrete proinflammatory cytokines, chemokines, and matrix metalloproteinase. J Immunol. 1997;159:2018.
25. Centers for Disease Control and Prevention. 1993: revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA. 1993;269:729.
26. Salemi M, Casoli C, Cattaneo E, Bertazzoni U. Identification of IIa and IIb molecular subtype of human T-cell leukemia virus type II among Italian injecting drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:516.
27. Cimarelli A, Zambruno G, Marconi A, Girolomoni G, Bertazzoni U, Giannetti A. Quantification by competitive PCR of HIV-1 proviral DNA in epidermal Langherans cells of HIV-infected patients. J Acquir Immune Defic Syndr. 1994;7:230.
28. Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, Albert J. MT-2 cell tropism as a prognostic marker for disease progression in HIV-1 infection. J Clin Microbiol. 1994;32:364.
29. Koup RA, Ho DD, Poli G, Fauci AS. Isolation and quantitation of HIV in peripheral blood. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current Protocols in Immunology. New York: J Wiley; 1993:12.2.1-12.2.11.
30. Hill CM, Deng H, Unutmaz D, et al. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J Virol. 1997; 71:6296.
31. Kinter AL, Poll G, Fox L, Hardy E, Fauci AS. HIV replication in IL-2 stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J Immunol. 1995;154:2448.
32. Aldovini A, Walker B. Techniques in HIV Research. Oxford, UK: Oxford University Press; 1990.
33. Greenberg SJ, Tendler CL, Manns A, et al. Altered cellular gene expression in human retroviral-associated leukemogenesis. In: Blatter WA, ed. Human Retrovirology: HTLV. New York: Raven; 1990:87.
34. Lal BR, Rudolph D, Buckner C, Pardi D, Hooper WC. Infection with human T-lymphotropic viruses leads to constitutive expression of leukemia inhibitory factor and interleukin-6. Blood. 1993;81: 1827.
35. Poli G, Fauci AS. Cytokine modulation of HIV expression. Semin Immunol. 1993;5:165.
36. + T-cells. Immunol Today. 1996;17:217.
37. Ward SG, Bakon K, Westwick J. Chemokines and T lymphocytes: more than an actraction. Immunity. 1998;9:1.
38. Ijichi S, Ramundo MB, Takahashi H, Hall WW. In vivo cellular tropism of human T-cell leukemia virus type II (HTLV-II). J Exp Med. 1992;176:293.
39. Noraz N, Verrier B, Fraisier C, Desgranges C. Cell surface phenotypic changes induced in H9 T-cells chronically infected with HTLV type I or co-infected with the two viruses. AIDS Res Hum Retroviruses. 1995;11:145.
40. Loetscher P, Seitz M, Baggiolini M, Moser B. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med. 1996;184:569.
41. De Rossi A, Saggioro D, Calabrò ML, Cenzato R, Chieco Bianchi L. Reciprocal activation of human T-lymphotropic viruses in HTLV-I transformed cells superinfected with HIV-1. J Acquir Immune Defic Syndr. 1991;4:380.
42. Dezzutti CS, Rudolph DL, Roberts CR, Lal RB. Characterization of human T-lymphotropic virus type I-and II-infected T-cell lines: antigenic, phenotypic, and genotypic analysis. Virus Res. 1993; 29:59.
43. Miller MD, Warmerdam MT, Gaston I, Green WC, Feinberg MB. The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med. 1994;179:101.
44. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals labile latent viral structure. Cell. 1990;61:213.
45. Zack JA, Haislip AM, Krogstad P, Chen IS. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent T-cells can function as intermediates in the retroviral life cycle. J Virol. 1992;66:1717.
46. + proliferative/cytotoxic T cell clone progresses in at least two distinct phases based on changes in function and phenotype of the infected cells. J Immunol. 1989;142:2279.
47. Poli G, Kinter A, Justement S, et al. Tumor necrosis factor α functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A. 1990;87: 782.
48. Tadmori W, Mondal D, Tadmori I, Prakash O. Transactivation of human immunodeficiency virus type 1 long terminal repeats by cell surface tumor necrosis factor α. J Virol. 1991;65:6425.
49. + cell anti-HIV activity: non lytic suppression of virus replication. AIDS Res Hum Retroviruses. 1992;8:1039.
50. Peterson PK, Gekker G, Chao CC, Schut R, Molitor W, Balfour HH. Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cultures. J Immunol. 1991;146:81.
51. Vyarkarnam A, McKeating J, Meager A, Beverly PC. Tumor necrosis factors (α, β) induced by HIV-1 in peripheral blood mononuclear cells potentiate virus replication. AIDS. 1990;4:21.
52. Osborn L, Kunkel S, Mabel GJ. Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc Natl Acad Sci U S A. 1989;86:2336.
53. Poli G, Kinter AL, Fauci AS. Interleukin-1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin-6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin-1 receptor antagonist. Proc Natl Acad Sci U S A. 1994;91:108.
54. Schuitemaker H, Kootstra NA, Koppelman MH, et al. Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages. J Clin Invest. 1992;89:1154.
55. + T-cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci U S A. 1995;92:10,985.
56. Unutmaz D, Pileri P, Abrignani S. Antigen-independent activation of naive and memory resting T-cells by a cytokine combination. J Exp Med. 1994;180:1159.
57. Moriuchi H, Moriuchi M, Fauci AS. Factors secreted by human T lymphotropic virus type I (HTLV-I)-infected cells can enhance or inhibit replication of HIV-1 in HTLV-I-uninfected cells: implications for in vivo coinfection with HTLV-I and HIV-1. J Exp Med. 1998;187:1689.
58. + T cells are a biologically relevant source of macrophage inflammatory protein-1α in vivo. J Immunol. 1999;162:5423.
59. Lewis MJ, Kaplan MH, Hall WW. Spontaneous β-chemokine production by lymphocytes from HTLV-II infected and HTLV-II/HIV-1 co-infected individuals [abstract]. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:A8 SP04.
60. Price DA, Klenerman P, Booth BL, Phillips RE, Sewell AK. Cytotoxic T lymphocytes, chemokines and antiviral immunity. Immunol Today. 1999;20: 212.
61. Nakao M, Nomiyana H, Shimada K. Structures of human genes coding for cytokine LD78 and their expression. Mol Cell Biol. 1990;10:3646.
62. 2-terminal heterogeneity: functional comparison of different natural isoforms. Eur J Biochem. 1999; 260:421.
63. Menten P, Struyf S, Schutyser E, et al. The LD78β isoform of MIP-1α is the most potent CCR5 agonist and HIV-1-inhibiting chemokine. J Clin Invest. 1999;104:R1.
64. Nibbs RJB, Yang J, Landau NR, Mao JH, Grahami GJ. LD78β, a non-allelic variant of human MIP-1α (LD78α), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem. 1999;274:17,478.